Mario Thomas, Ph.D., Dsa, C.Dir. Email and Phone Number
Mario Thomas, Ph.D., Dsa, C.Dir. work email
- Valid
- Valid
- Valid
- Valid
Mario Thomas, Ph.D., Dsa, C.Dir. personal email
- Valid
STRATEGIC EXECUTIVE - BOARD GOVERNANCEWith over 30 years of leadership experience in the life sciences industry, Mario Thomas has built and led teams that develop purposeful, innovative and leading-edge technologies. As Founder, President and Chairman of Precision Biomonitoring Inc., he continues to leverage his experience, insights and industry knowledge to inspire his teams to continue pushing for advanced innovation that will result in improved outcomes for partners and stakeholders. By building strategic alliances with partners on both domestic and international stages, Mario understands the importance of collaboration and is continuously driven by the pursuit of a common goal that benefits all. Via Mario’s dynamic leadership, Precision Biomonitoring has successfully developed cutting-edge technologies that will continue to keep Canadian families, communities, and employees healthy and safe, not only during COVID-19, but into the future. Specialties: Strategy, Commercialization, Management, Team Leadership, Corporate Growth, Business Development, Partnerships, Mergers & Acquisitions, Profit & Loss Management, Board of Directors Interface, Tactical Negotiations & Closures, Sales & Marketing, Global Market Expansion, Product Research & Development, Return on Investment, Financial Restructuring, High-Growth Ventures, Product Commercialization
-
Co-Founder, President And Board ChairPrecision Biomonitoring Inc.Cambridge, On, Ca
-
Co-Founder, President & Board ChairPrecision Biomonitoring Inc. Jun 2021 - PresentCambridge, Ontario, Canada
-
Co-Founder, Chief Executive Officer And Board DirectorPrecision Biomonitoring Inc. Nov 2016 - Jul 2021Guelph, OntarioPrecision Biomonitoring provides the environmental and aquaculture sectors with molecular point-of-need tools that detect environmental DNA (eDNA) for the identification of invasive, keystone and at-risk species, and pathogens in aquatic systems. The molecular point-of-need tools are simple to use, give more definitive species identification, under 2 hours and at lower costs of traditional methods, and without having to send samples to a central lab.
-
Chief Executive Officer And Board Director, Biodiversity InstituteUniversity Of Guelph Apr 2015 - Apr 2018Guelph, CanadaThe Biodiversity Institute is a world leader in understanding the biodiversity of the planet and utilizes that knowledge to develop innovative technologies that provide solutions to problems facing industry, governments and society at large. The Biodiversity Institute leads biodiversity research and development based on genetic sequencing and barcoding technology.The Institute offers bioservices dependent on species identification and state-of-the-art training in biodiversity in both the academic and private sectors. -
President And Board DirectorProteocyte Ai Apr 2013 - Apr 2015Toronto, Canada AreaProteocyte is commercializing a novel diagnostic technology, Straticyte™, to provide robustprognostic assessment of multiple cancers. With Straticyte™ testing, clinicians choosetreatment strategies to best match individual tumor biology of cancer patients. Adoption ofStraticyte™ will save lives, spare patients adverse effects of radical therapy, and significantlyreduce costs for healthcare payers.Straticyte™ for oral cancer is the first and only molecular diagnostic test for oral precancerous lesions that provides an objective and accurate prediction score as evidenced by retrospective studies. Unlike standard of care based on subjective visual assessment methods, Straticyte™ uses the power of proteomics to provide a reliable assessment of risk for progression to cancer and help clinicians save lives, improve quality of life and reduce healthcare costs.
-
Founding Board ChairInternational Commercialization Alliance Mar 2011 - Mar 2013In 2011, I conceived, architect-ed and founded the International Commercialization Alliance, bringing together 49 founding organizations from 18 countries. The purpose of the alliance is to help continuously improve how its members commercialize research outcomes by sharing knowledge learned from both successes and failures through continuous global collaborations on exemplary practices and innovative models in commercialization.
-
Senior Vice-PresidentOntario Centres Of Excellence Inc. Apr 2009 - Mar 2013Toronto, Canada Area• Obtained several new sources of funding• Developed a multitude of partnerships and • Re-organized the structure to engage the clients, partners and stakeholders• Developed and implemented a new strategic and operating planning process• Created a sector strategy and four sector advisory boards
-
Managing Director And Board MemberCentre Of Excellence For Commercialization Of Research (Ccr) Apr 2009 - Mar 2013Toronto, Canada• Built the Centre of Excellence for Commercialization (CCR) from the ground up • Over a period of four years, CCR has delivered $7 million of funding to 86 companies and services to 992, generating over 1500 new jobs, $28 million of co-investment leverage and $149 million of follow-on investments by third party investors. Clients have increased their sales revenue by $56 million.
-
Vice President & PartnerT2C2/Bio Inc. Oct 2002 - Apr 2009A $100M venture fund which focuses on early-stage life sciences investments in Canada, Europe, and Israel.• Devised strategy for as many as twelve, multi-million dollar investment candidates in Bio/Agro, chemistry, medical equipment, genomics, and therapeutic products while reducing corporate risk.• Brought together some of the world’s largest institutional investors and venture capital funds to co-invest in rounds of over $30 Million in life sciences.
-
Chief Executive Officer And Board ChairEntomed Sa May 2000 - Sep 2002Strasbourg, Grand Est, FranceWorld leader in the discovery and development of medicines derived from the biology and chemical diversity of insects.• Built a robust discovery and early product development platform with significant automation of routine operations, increasing the rate of discoveries and improving efficiency by over 100x.• Executed a strategic plan to successfully transfer technology from a university model to a commercial project, raising €20 Million in venture capital financing and €4.3 million in grants.
-
Chief Executive Officer And Board DirectorTerragen Discovery Inc. Jun 1998 - May 2000Vancouver, British Columbia, CanadaInternational biotechnology firm with global projects in the fight against infections.• Improved corporate value through a series of strategic manoeuveurs including the multi-million dollar acquisitions of a US competitor to obtain broad issued patents enhancing core technology and a UK company for its downstream drug discovery capabilities.• Established two significant research collaborations raising $13 Million in venture capital advancing anti-infective research while tripling the return on investment in the final corporate exit plan.
-
Vice President, Strategy Planning & Business Development, Therapeutics UnitBiochem Pharma Inc. Sep 1993 - May 1998An international biopharmaceutical company dedicated to the research, development, and commercialization of products for the prevention and treatment of human illnesses, with a focus in cancer and infectious diseases.• Implemented a strategic planning process incorporating business development objectives while integrating long-term strategy with annual operating plans.• Concluded 20 diverse, lucrative transactions in different countries in the world over a 5-year period • Launched the Canadian commercial operation for the number one drug, 3TC used against HIV and aids becoming a multi-billion dollar product worldwide and more successful than any other treatment while significantly reducing the death rate.
-
Sales & Marketing ManagementBurroughs Wellcome Inc. Aug 1987 - Aug 1993MARKETING MANAGER, SPECIALTY PRODUCTS, & NEW PRODUCTS - MEDICAL DIVISIONPromoted multiple times to senior leadership roles in marketing, business development, and branding.
-
Product DirectorJohnson & Johnson Inc. Aug 1979 - Aug 1987MARKETING, PRODUCT DEVELOPMENT & COMMERCIALIZATION – HOSPITAL PRODUCTS DIVISIONElevated progressively to management roles in marketing, advertising, and commercialization.
Mario Thomas, Ph.D., Dsa, C.Dir. Skills
Mario Thomas, Ph.D., Dsa, C.Dir. Education Details
-
Corporate Governance -
Business Administration -
Chemistry
Frequently Asked Questions about Mario Thomas, Ph.D., Dsa, C.Dir.
What company does Mario Thomas, Ph.D., Dsa, C.Dir. work for?
Mario Thomas, Ph.D., Dsa, C.Dir. works for Precision Biomonitoring Inc.
What is Mario Thomas, Ph.D., Dsa, C.Dir.'s role at the current company?
Mario Thomas, Ph.D., Dsa, C.Dir.'s current role is Co-Founder, President and Board Chair.
What is Mario Thomas, Ph.D., Dsa, C.Dir.'s email address?
Mario Thomas, Ph.D., Dsa, C.Dir.'s email address is ma****@****rio.org
What schools did Mario Thomas, Ph.D., Dsa, C.Dir. attend?
Mario Thomas, Ph.D., Dsa, C.Dir. attended Université Laval, Hec Montréal, Université Laval.
What are some of Mario Thomas, Ph.D., Dsa, C.Dir.'s interests?
Mario Thomas, Ph.D., Dsa, C.Dir. has interest in Solving Complex Problems, Horses, Team Work, Connecting People, Biking, Great Food, What's Next.
What skills is Mario Thomas, Ph.D., Dsa, C.Dir. known for?
Mario Thomas, Ph.D., Dsa, C.Dir. has skills like Strategy, Start Ups, Commercialization, Business Development, Mergers And Acquisitions, Entrepreneurship, Partnerships, Market Research, Strategic Planning, Leadership, Venture Capital, Business Planning.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial